L. Weiss

发表

Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV

D. Costagliola, S. Grabar, G. Pialoux, 2009, AIDS.

HIV infection in older patients in the HAART era.

D. Costagliola, S. Grabar, L. Weiss, 2006, The Journal of antimicrobial chemotherapy.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy

C. Charpentier, L. Bélec, M. Jenabian, 2011, Scandinavian journal of infectious diseases.

The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.

M. Kazatchkine, L. Gutmann, L. Bélec, 1998, Antiviral research.

In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2–treated HIV patients

S. Maiella, Y. Lévy, L. Rogge, 2010, Proceedings of the National Academy of Sciences.

Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4

D. Costagliola, Y. Lévy, C. Pradier, 2009, Journal of acquired immune deficiency syndromes.

Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy

D. Costagliola, M. Alhenc-Gelas, C. Didier, 2016, Journal of acquired immune deficiency syndromes.

Level of double negative T cells, which produce TGF-&bgr; and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection

D. Scott‐Algara, M. Müller-Trutwin, L. Meyer, 2012, AIDS.

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

C. Fagard, C. Rouzioux, Y. Lévy, 2009, AIDS.

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy *

C. Charpentier, L. Bélec, P. Tisserand, 2008, HIV medicine.

Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure

C. Charpentier, C. Petropoulos, Wei Huang, 2009, Antimicrobial Agents and Chemotherapy.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study

V. Calvez, C. Katlama, Y. Yazdanpanah, 2019, Pharmacotherapy.

Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

F. Carrat, C. Michelet, D. Guyader, 2010, Journal of hepatology.

Combined Heterozygous Deficiency of the Classical Complement Pathway Proteins C2 and C4

M. Kazatchkine, V. Frémeaux-Bacchi, L. Weiss, 1997, Journal of Clinical Immunology.

Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy

C. Rouzioux, S. Pol, H. Fontaine, 2006, AIDS.

Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection.

M. Kazatchkine, L. Weiss, H. Sadeghi, 1995, The Journal of infectious diseases.

Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART

R. Tubiana, E. Lanoy, D. Costagliola, 2013, AIDS.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults

T. Harrer, D. Podzamczer, C. Katlama, 2016, Medicine.

Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.

M. Kazatchkine, V. Frémeaux-Bacchi, L. Weiss, 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Plasma sVCAM‐1, antiretroviral therapy and mortality in HIV‐1‐infected West African adults

S. Eholie, X. Anglaret, C. Danel, 2022, HIV medicine.

Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

M. Kazatchkine, L. Bélec, L. Weiss, 2001, The Journal of infectious diseases.

Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control

M. Müller-Trutwin, L. Meyer, O. Lambotte, 2022, The Journal of clinical investigation.

Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection.

C. Blondin, M. Kazatchkine, L. Weiss, 1997, The Journal of infectious diseases.

Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4

D. Costagliola, S. Grabar, G. Pialoux, 2017, PLoS ONE.

CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era

C. Delaugerre, L. Cuzin, D. Costagliola, 2018, AIDS.

HIV infection and COVID-19: risk factors for severe disease

L. Slama, D. Salmon, L. Weiss, 2020, AIDS.

Immediate T-Helper 17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells.

Z. Trajanoski, H. Hackl, P. Kellam, 2015, The Journal of infectious diseases.

Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients.

D. Scott‐Algara, Y. Madec, C. Didier, 2017, The Journal of infection.

Molecular Basis of a Selective C1s Deficiency Associated with Early Onset Multiple Autoimmune Diseases1

W. Fridman, A. Prieur, P. Quartier, 2001, The Journal of Immunology.

Trends in Post-Infection CD4 Cell Counts and Plasma HIV-1 RNA Levels in HIV-1–Infected Patients in France Between 1997 and 2005

D. Costagliola, L. Weiss, E. Rouveix, 2009, Journal of acquired immune deficiency syndromes.

Mouse monoclonal antibodies to the human C3b receptor.

M. Kazatchkine, C. Boucheix, L. Weiss, 1985, Molecular immunology.

High Activation of (cid:13)(cid:14) T Cells and the (cid:13)(cid:14) 2pos T-Cell Subset Is Associated With the Onset of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome, ANRS 12153 CAPRI NK

Y. Madec, L. Weiss, D. Laureillard, 2020 .

Chronic urticaria and moderate leukocytoclastic vasculitis associated with C3 nephritic factor activity.

M. Rybojad, P. Morel, L. Borradori, 1989, Archives of dermatology.

0.1. Association of plasma sVCAM-1 and sCD14 with mortality in HIV-1 infected West African adults with high CD4 counts.

C. Rouzioux, S. Eholie, C. Dunyach-Rémy, 2020, Journal of acquired immune deficiency syndromes.

Phenotype alterations in regulatory T-cell subsets in primary HIV infection and identification of Tr1-like cells as the main interleukin 10-producing CD4+ T cells.

D. Scott‐Algara, G. Petitjean, C. Didier, 2015, The Journal of infectious diseases.

Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells.

L. Weiss, C. Carbonneil, H. Saidi, 2004, International immunology.

Increased Polymorphism in the HR-1 gp41 env Gene Encoding the Enfuvirtide (T-20) Target in HIV-1 Variants Harboring Multiple Antiretroviral Drug Resistance Mutations in the pol Gene

C. Charpentier, M. Kazatchkine, L. Bélec, 2007, Journal of acquired immune deficiency syndromes.

The human C3b receptor (CR1).

M. Kazatchkine, M. Appay, J. Bariéty, 1989, Advances in nephrology from the Necker Hospital.

Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serumfree cultures of autologous monocytes

J. Cavaillon, M. Kazatchkine, L. Weiss, 1989, European journal of immunology.

Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus

M. Kazatchkine, V. Frémeaux-Bacchi, L. Weiss, 1996, Lupus.

Human CD90 Identifies Th17/Tc17 T Cell Subsets That Are Depleted in HIV-Infected Patients

N. Chaput, D. Klatzmann, Y. Lévy, 2012, The Journal of Immunology.

PatientsSubsets That Are Depleted in HIV-Infected Human CD90 Identifies Th17/Tc17 T Cell

N. Chaput, D. Klatzmann, Y. Lévy, 2011 .

Complement enhancement of HIV infection is mediated by complement receptors.

M. Kazatchkine, N. Thieblemont, L. Weiss, 1993, Immunopharmacology.

Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12–26 study

M. Kazatchkine, P. Van de Perre, S. Diagbouga, 2003, AIDS.

Induction of cell‐associated interleukin 1 through stimulation of the adhesion‐promoting proteins LFA‐1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes

M. Kazatchkine, L. Weiss, E. Fischer, 1990, European journal of immunology.

Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz

M. Kazatchkine, G. Peytavin, L. Weiss, 2002, HIV medicine.

Flow-Cytometric Assessment ofin VivoCytokine-Producing Monocytes in HIV-Infected Patients

C. Estcourt, N. Thieblemont, L. Weiss, 1997 .

Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa.

M. Kazatchkine, L. Weiss, M. Karmochkine, 2004, European journal of gastroenterology & hepatology.

Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation.

M. Kazatchkine, A. Vazquez, J. Delfraissy, 1987, Journal of immunology.

Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4‐deficient patients with systemic lupus erythematosus (SLE)

M. Kazatchkine, P. Rémy, F. Ariey, 2001, Clinical and experimental immunology.

Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2.

J. Piette, W. Fridman, L. Mouthon, 2002, The American journal of medicine.

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

M. Kazatchkine, D. Costagliola, S. Grabar, 2000, Annals of Internal Medicine.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Flow-cytometric assessment of in vivo cytokine-producing monocytes in HIV-infected patients.

C. Estcourt, N. Thieblemont, L. Weiss, 1997, Clinical immunology and immunopathology.

Renal aspergilloma in AIDS.

A. Hernigou, M. Kazatchkine, L. Weiss, 1993, American Journal of Medicine.

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.

A. Winston, P. Reiss, M. Guiguet, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS.

M. Kazatchkine, J. Mikol, J. Thiebaut, 2002, The Journal of infection.

The split personality of regulatory T cells in HIV infection.

L. Weiss, M. Chevalier, 2013, Blood.

Unusual pulmonary Enterocytozoon bieneusi microsporidiosis in an AIDS patient: case report and review.

M. Cornet, L. Weiss, C. Piketty, 2004, Scandinavian journal of infectious diseases.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir

C. Rouzioux, D. Costagliola, A. Mélard, 2010, Journal of medical virology.

Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry.

Thomas Le Saux, Gérard Pons, T. Le Saux, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients

M. Kazatchkine, L. Bélec, J. Duong van Huyen, 2000 .

Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy.

M. Kazatchkine, P. Bruneval, M. Bélair, 2003, American journal of clinical pathology.

Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.

M. Duracinsky, F. Gillaizeau, L. Weiss, 2012, AIDS research and human retroviruses.

Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.

C. Charpentier, L. Bélec, L. Weiss, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

M. Kazatchkine, F. Clavel, G. Peytavin, 1999, AIDS.

Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection.

M. Kazatchkine, L. Weiss, P. Giral, 1995, Clinical immunology and immunopathology.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Predictors of CD4 count change over 8 months of follow up in HIV‐1‐infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin‐2

B. Gazzard, F. Antunes, Z. Fox, 2007, HIV medicine.

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

M. Kazatchkine, L. Bélec, J. Gilquin, 1998, AIDS.

Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients

M. Kazatchkine, L. Bélec, G. Pialoux, 2000 .

Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

M. Kazatchkine, P. Bruneval, L. Bélec, 2001 .

Genital and oral erosions induced by foscarnet

M. Kazatchkine, J. Gilquin, L. Weiss, 1990, The Lancet.

High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy.

M. Kazatchkine, L. Bélec, L. Weiss, 2000, The Journal of infectious diseases.

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

W. Fridman, H. Nivet, V. Frémeaux-Bacchi, 2005, Journal of the American Society of Nephrology : JASN.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

D. Podzamczer, J. Gatell, J. Mallolas, 2015, The Lancet. Infectious diseases.

Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.

M. Kazatchkine, F. Clavel, G. Peytavin, 2000, AIDS.

Complement activation by gp160 glycoprotein of HIV-1.

M. Kazatchkine, N. Thieblemont, L. Weiss, 1993, AIDS research and human retroviruses.

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

C. Rouzioux, Y. Lévy, J. Lelièvre, 2009, The Journal of clinical investigation.

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation

C. Rouzioux, D. Scott‐Algara, L. Meyer, 2013, PLoS pathogens.

Identification of Cryptic MHC I–restricted Epitopes Encoded by HIV-1 Alternative Reading Frames

P. Rohrlich, F. Lemonnier, O. Schwartz, 2004, The Journal of experimental medicine.

Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients.

Y. Lévy, L. Caccavelli, L. Weiss, 2004, Blood.

Potential Role of Vδ2+ γδ T Cells in Regulation of Immune Activation in Primary HIV Infection

D. Scott‐Algara, C. Didier, P. Girard, 2017, Front. Immunol..

Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells.

M. Kazatchkine, N. Thieblemont, L. Weiss, 1995, Journal of immunology.

Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-α are potent inducers of HIV-specific CD8 T cells

C. Rouzioux, P. Langlade‐Demoyen, L. Weiss, 2003, AIDS.

Episomal HPV16 responsible for aggressive and deadly metastatic anal squamous cell carcinoma evidenced in peripheral blood

A. Nicolas, B. Rance, M. Wack, 2021, Scientific Reports.

T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection

C. Rouzioux, D. Costagliola, C. Didier, 2014, AIDS.

Persistent Expansion, in a Human Immunodeficiency Virus-Infected Person, of Vβ-Restricted CD4+CD8+ T Lymphocytes that Express Cytotoxicity-Associated Molecules and Are Committed to Produce Interferon-γ and Tumor Necrosis Factor-α

M. Kazatchkine, M. Gougeon, L. Weiss, 1998 .

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control

C. Rouzioux, D. Costagliola, P. Girard, 2015, AIDS.

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial

É. Oksenhendler, Y. Lévy, C. Goujard, 1999, The Lancet.

Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy.

M. Kazatchkine, P. Girard, L. Weiss, 1999, The Journal of infectious diseases.

γδ T-cell subsets in HIV controllers: potential role of Tγδ17 cells in the regulation of chronic immune activation.

D. Scott‐Algara, C. Didier, P. Girard, 2019, AIDS.

[Exploration of the complement system in clinical practice].

V. Frémeaux-Bacchi, L. Weiss, J. Blouin, 1994, Archives de pédiatrie.

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors

C. Charpentier, P. Tisserand, L. Weiss, 2010, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.

E. Tartour, J. Taieb, S. Pernot, 2014, Clinics and research in hepatology and gastroenterology.

A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients

N. Dupin, O. Lortholary, O. Launay, 2009, Antiviral therapy.

Complete inherited deficiency of the fourth complement component in a child with systemic lupus erythematosus and his disease-free brother in a North African family

M. Kazatchkine, V. Frémeaux-Bacchi, C. Loirat, 1994, Journal of Clinical Immunology.

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men

S. Grabar, J. Taieb, H. Péré, 2018, British Journal of Cancer.

Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study.

S. Grabar, J. Taieb, H. Péré, 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

High Activation of γδ T Cells and the γδ2pos T-Cell Subset Is Associated With the Onset of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome, ANRS 12153 CAPRI NK

D. Scott‐Algara, Y. Madec, F. Barré-Sinoussi, 2019, Front. Immunol..

Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV‐1 infection: results from a longitudinal study in the French ANRS Primo cohort

F. Raffi, L. Meyer, P. Delobel, 2020, Journal of the International AIDS Society.

HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection

Y. Lévy, J. Lelièvre, H. Kared, 2008, AIDS.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

V. Calvez, D. Podzamczer, C. Delaugerre, 2020, The Journal of antimicrobial chemotherapy.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

P. Morlat, C. Rouzioux, Y. Lévy, 2012, AIDS.

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.

D. Costagliola, Y. Lévy, C. Pradier, 2010, The Journal of antimicrobial chemotherapy.

Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048–079 Trials)*

É. Oksenhendler, Y. Lévy, C. Goujard, 2007, AIDS.

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial

É. Oksenhendler, C. Rouzioux, Y. Lévy, 2003, AIDS.

Decreased Expression of the Membrane Inhibitor of Complement‐Mediated Cytolysis CD59 on T‐lymphocytes of HIV‐Infected Patients

M. Kazatchkine, H. Okada, T. Hattori, 1992, AIDS.

Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct

P. van Endert, P. Rohrlich, F. Lemonnier, 2009, AIDS.

Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha.

M. Kazatchkine, M. Gougeon, L. Weiss, 1998, The Journal of infectious diseases.

[HPV (Human Papilloma Virus) implication in other cancers than gynaecological].

E. Tartour, J. Thariat, A. Bats, 2015, La Revue de medecine interne.

Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.

M. Kazatchkine, V. Frémeaux-Bacchi, L. Weiss, 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.

G. Deschênes, P. Niaudet, P. Coppo, 2004, Journal of the American Society of Nephrology : JASN.

Human complement factor H deficiency associated with hemolytic uremic syndrome.

M. Kazatchkine, G. Deschênes, V. Frémeaux-Bacchi, 1998, Journal of the American Society of Nephrology : JASN.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

R. Tubiana, C. Katlama, B. Autran, 2019, npj Vaccines.

Missed opportunities for HIV testing in patients newly diagnosed with HIV in Morocco

R. Bensghir, L. Weiss, D. Laureillard, 2021, BMC Infectious Diseases.

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

É. Oksenhendler, C. Katlama, D. Neau, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam–hepatitis C)

D. D. Des Jarlais, P. Vickerman, J. Molès, 2020, BMJ Open.

Immunological and virological features of HIV‐infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor‐based therapy

C. Rouzioux, M. Kazatchkine, J. Gilquin, 2002, HIV medicine.

CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell‐like characteristics

L. Weiss, N. Haeffner‐cavaillon, P. Ancuța, 2000, European journal of immunology.

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.

C. Katlama, D. Costagliola, S. Grabar, 2019, Journal of Infectious Diseases.

Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients

M. Kazatchkine, D. Heudes, P. Bruneval, 2006, Modern Pathology.

Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

Y. Yazdanpanah, C. Rouzioux, H. Mouquet, 2022, Nature Communications.

CD14lowCD16high: A cytokine‐producing monocyte subset which expands during human immunodeficiency virus infection

C. Estcourt, N. Thieblemont, L. Weiss, 1995, European journal of immunology.

Association of Plasma sVCAM-1 and sCD14 with Mortality in HIV-1 Infected West African Adults with High CD4 Counts

C. Rouzioux, S. Eholie, C. Dunyach-Rémy, 2020, SSRN Electronic Journal.

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.

M. Kazatchkine, P. Bruneval, L. Bélec, 2001, AIDS.

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

C. Charpentier, L. Weiss, 2010, Infection and drug resistance.

Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection

M. Müller-Trutwin, L. Meyer, O. Lambotte, 2019, Nature Metabolism.

[Schnitzler syndrome with genetic C4 deficiency. 2 cases].

C. Lebbé, M. Rybojad, P. Morel, 1993, Annales de dermatologie et de venereologie.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

C. Delaugerre, C. Katlama, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection

M. Egger, M. Kazatchkine, D. Costagliola, 2005, Journal of acquired immune deficiency syndromes.

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis"

A. Bats, S. Hans, C. Badoual, 2019, British Journal of Cancer.

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

D. Lebeaux, E. Thervet, L. Mouthon, 2022, Clinical Microbiology and Infection.

Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy

C. Rouzioux, D. Costagliola, Y. Lévy, 2010, PloS one.

HPV-circulating tumoural DNA by droplet-based digital polymerase chain reaction, a new molecular tool for early detection of HPV metastatic anal cancer? A case report.

H. Péré, V. Taly, D. Veyer, 2019, European Journal of Cancer.

CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden

D. Scott‐Algara, C. Didier, F. Barré-Sinoussi, 2016, Front. Immunol..

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.

C. Charpentier, L. Weiss, F. Damond, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men

P. Easterbrook, K. Squires, S. Walmsley, 2009, AIDS.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

R. Breban, A. Samri, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase pol gene.

M. Kazatchkine, F. Mbopi-Kéou, F. Clavel, 2002, Journal of Acquired Immune Deficiency Syndromes.

Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles

V. Appay, M. Ungeheuer, O. Lambotte, 2016, PloS one.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

R. Tubiana, C. Katlama, B. Autran, 2019, npj Vaccines.

HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro.

M. Kazatchkine, J. Gilquin, L. Weiss, 1989, AIDS.

Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy

C. Charpentier, L. Bélec, P. Tisserand, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues.

M. Kazatchkine, P. Bruneval, J. Duong van Huyen, 2002, AIDS.

[Idiopathic CD4 lymphocytopenia].

M. Kazatchkine, L. Weiss, C. Piketty, 1994, Presse medicale.

Sporotrichosislike infection caused by Mycobacterium avium in the acquired immunodeficiency syndrome.

M. Kazatchkine, L. Weiss, C. Piketty, 1993, Archives of Dermatology.

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

C. Charpentier, L. Weiss, 2010, Infection and drug resistance.

Infection and Drug Resistance Dovepress Extended Use of Raltegravir in the Treatment of Hiv-1 Infection: Optimizing Therapy Infection and Drug Resistance 2010:3 Overview of Pharmacology and Mechanism of Action of Raltegravir Mechanism of Action

C. Charpentier, L. Weiss, Charlotte Charpentier, 2022 .

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis"

A. Bats, S. Hans, C. Badoual, 2019, British Journal of Cancer.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

R. Tubiana, C. Katlama, B. Autran, 2019, npj Vaccines.

Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy

C. Rouzioux, D. Costagliola, Y. Lévy, 2010, PloS one.

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

R. Tubiana, C. Katlama, F. Raffi, 2020, The Journal of antimicrobial chemotherapy.

Factors associated with being overweight and obesity in people living with HIV on antiretroviral therapy : socio-clinical, inflammation, and metabolic markers.

A. Maignan, Y. Yazdanpanah, D. Neau, 2021, The Journal of infectious diseases.

Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4

D. Costagliola, Y. Lévy, C. Pradier, 2009, Journal of acquired immune deficiency syndromes.

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.

M. Kazatchkine, L. Bélec, J. Duong van Huyen, 2000, AIDS.

Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men

S. Grabar, J. Taieb, H. Péré, 2018, British Journal of Cancer.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy

C. Charpentier, L. Bélec, P. Tisserand, 2011, Scandinavian journal of infectious diseases.

Comparative study ofin vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA)

M. Kazatchkine, L. Weiss, P. Goldschmidt, 1991, Agents and Actions.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

P. Morlat, C. Rouzioux, Y. Lévy, 2012, AIDS.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir

C. Rouzioux, D. Costagliola, A. Mélard, 2010, Journal of medical virology.